Business Context and Reporting Period
This Form 8-K Current Report is filed by Kulicke and Soffa Industries, Inc. (KLIC) on October 28, 2025. The report discloses significant changes in corporate leadership, specifically the retirement of the Chief Executive Officer and the appointment of an interim successor.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and personnel changes.
Material Changes
- CEO Retirement: Dr. Fusen Chen will retire as President, CEO, and Board member effective December 1, 2025, citing health reasons.
- Interim CEO Appointment: Lester Wong, currently Executive Vice President and CFO, has been appointed Interim CEO effective immediately.
- Succession Plan: The Board will conduct a search for a permanent CEO among internal and external candidates.
Compensation, Risks, and Unusual Items
Dr. Fusen Chen (Retiring CEO)
- Advisory Role: Will serve as a Board advisor for 12 months post-retirement.
- Advisory Fee: US$75,000 per month. Payments continue if terminated without cause.
- Bonus: Eligible for a pro-rated annual cash bonus based on target opportunity.
- Equity: Outstanding performance share units remain eligible for vesting; unvested restricted stock units are forfeited.
- Benefits: Health insurance coverage for 18 months.
Lester Wong (Interim CEO)
- Stipend: S$35,000 per month for service as Interim CEO until a permanent CEO is appointed.
- Equity Grant: S$600,000 in restricted stock units vesting in full after one year, subject to continued employment.
- Acceleration: RSUs vest immediately if terminated without Cause or if he resigns with Good Reason.
Risks and Contingencies
The primary risk disclosed is the leadership transition. The filing notes that Dr. Chen will support Mr. Wong to ensure a smooth handover. No other material risks or contingencies are detailed in this specific report.
Investor Verification Checklist
- Verify the timeline for the permanent CEO search and any interim performance metrics.
- Review the total cost of the transition package for Dr. Chen (advisory fees, bonus, and benefits) against the company's cash position.
- Confirm the vesting conditions and potential acceleration triggers for Mr. Wong's S$600,000 RSU grant.
- Monitor subsequent filings for the appointment of a permanent CEO and any changes to strategic direction.